Fisher Asset Management LLC Grows Position in Revvity, Inc. (NYSE:RVTY)

Fisher Asset Management LLC boosted its stake in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 41.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,248 shares of the company's stock after purchasing an additional 16,633 shares during the quarter. Fisher Asset Management LLC's holdings in Revvity were worth $6,389,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Janus Henderson Group PLC boosted its position in shares of Revvity by 1.7% during the 3rd quarter. Janus Henderson Group PLC now owns 6,335,302 shares of the company's stock worth $809,332,000 after acquiring an additional 108,401 shares in the last quarter. State Street Corp boosted its position in shares of Revvity by 0.3% in the 3rd quarter. State Street Corp now owns 5,180,169 shares of the company's stock valued at $661,767,000 after purchasing an additional 17,832 shares during the period. Geode Capital Management LLC boosted its position in shares of Revvity by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 2,863,793 shares of the company's stock valued at $364,569,000 after purchasing an additional 25,078 shares during the period. EdgePoint Investment Group Inc. boosted its position in shares of Revvity by 34.6% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 2,685,775 shares of the company's stock valued at $343,108,000 after purchasing an additional 690,534 shares during the period. Finally, RGM Capital LLC boosted its position in shares of Revvity by 3.2% in the 3rd quarter. RGM Capital LLC now owns 980,858 shares of the company's stock valued at $125,305,000 after purchasing an additional 30,000 shares during the period. 86.65% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Transactions at Revvity

In related news, insider Tajinder S. Vohra sold 5,492 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total value of $641,520.52. Following the completion of the transaction, the insider now directly owns 19,652 shares of the company's stock, valued at $2,295,550.12. This trade represents a 21.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Joel S. Goldberg sold 15,170 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the transaction, the insider now directly owns 33,400 shares of the company's stock, valued at $4,232,782. The trade was a 31.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.60% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on RVTY shares. Sanford C. Bernstein cut Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 target price for the company. in a research report on Friday, January 10th. KeyCorp upped their target price on Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Raymond James reissued an "outperform" rating and issued a $145.00 target price (up from $140.00) on shares of Revvity in a research report on Monday, February 3rd. Barclays increased their price objective on Revvity from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. Finally, Bank of America raised Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price objective for the company in a research report on Friday, December 13th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Revvity has an average rating of "Moderate Buy" and a consensus price target of $136.25.

Revvity Stock Performance

Shares of RVTY stock traded up $4.74 during trading hours on Friday, reaching $117.95. 1,399,074 shares of the company's stock were exchanged, compared to its average volume of 935,202. The company has a market cap of $14.17 billion, a P/E ratio of 53.37, a price-to-earnings-growth ratio of 3.82 and a beta of 1.06. The company's 50 day moving average is $116.90 and its two-hundred day moving average is $118.23. Revvity, Inc. has a 1 year low of $97.32 and a 1 year high of $129.50. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03.

Revvity (NYSE:RVTY - Get Free Report) last issued its earnings results on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the prior year, the business posted $1.25 earnings per share. Equities research analysts anticipate that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.24%. The ex-dividend date is Thursday, April 17th. Revvity's dividend payout ratio (DPR) is 12.67%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.